AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

AbbVie Inc.NYSE: ABBV

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 85.0%

Gross margin was 85.0% in Q3 FY2026, up 18.6 pp from a year earlier. On a trailing-twelve-month basis it was 76.3%, up 6.5 pp year over year. Over 3 fiscal years it widened by 0.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
85.0%+10.2 pp QoQ
Last fiscal yearDec 2025
70.2%+0.2 pp YoY
LTMSep 2026
76.3%+6.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+18.6 pp——
1 year+0.2 pp——
3 years+0.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
70.2%
Year-over-year change
+0.2pp

Gross Margin vs competitors

How ABBV compares with its peers on the latest reported figures

  • ABBV's LTM Sep 2026 gross margin of 76.3% is the 3rd highest of the 10 companies compared; the peer median is 73.2%.
  • Its year-over-year change of +6.5 pp is the 2nd highest of 10, against a peer median of +0.7 pp.
  • Over three fiscal years its change of +0.2 pp compares with a peer median of +1.7 pp.
ABBV Competitors Peer median
Gross Margin for ABBV and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202683.4% +0.8 pp+6.3 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
ABBVAbbVie Inc.LTM Sep 202676.3% +6.5 pp+0.2 pp
MRKMerck & Co., Inc.LTM Jun 202675.4% -0.1 pp+1.3 pp
NVSNovartis AGLTM Jun 202674.4% -1.8 pp+1.7 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
GSKGSK plcLTM Jun 202672.7% +1.4 pp+5.0 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202670.2% -0.1 pp-7.0 pp
JNJJohnson & JohnsonLTM Sep 202668.8% +0.7 pp-1.4 pp
Peer median (excluding ABBV) 73.2%+0.7 pp+1.7 pp

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.2B58.05B54.32B56.33B61.16B
Cost of Revenue17.45B17.41B20.42B16.9B18.2B
Gross Profit38.75B40.64B33.9B39.43B42.96B
Gross Margin69.0%70.0%62.4%70.0%70.2%
Research & Development8.05B6.51B7.68B12.79B9.1B
Selling, General & Admin12.35B15.26B12.87B14.75B14.01B
Operating Expenses20.83B22.52B21.15B30.29B22.87B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
EBITDA23.93B24.17B17.17B14.91B17.63B
EBITDA Margin42.6%41.6%31.6%26.5%28.8%
Operating Income17.92B18.12B12.76B9.14B20.09B
Operating Margin31.9%31.2%23.5%16.2%32.8%
Interest Income39M186M540M648M266M
Interest Expense2.42B2.23B2.22B2.81B2.89B
Other Income / Expenses(4.94B)(4.64B)(6.51B)(5.42B)(13.49B)
Income Before Tax12.99B13.48B6.25B3.72B6.6B
Pre-Tax Margin23.1%23.2%11.5%6.6%10.8%
Income Tax Expense1.44B1.63B1.38B(570M)2.36B
Net Income11.54B11.84B4.86B4.28B4.23B
Net Margin20.5%20.4%9.0%7.6%6.9%
EPS (Basic)6.486.652.732.402.37
EPS (Diluted)6.456.632.722.392.37
Weighted Avg Shares1.77B1.77B1.77B1.77B1.77B
Weighted Avg Shares (Diluted)1.78B1.78B1.77B1.77B1.77B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.